Join us in-person in Berlin, Germany for the Cell & Gene Therapy International Europe 2026 event.
Evotec at CGTI Europe 2026
Oral Presentation
Off-The-Shelf Immune-Shielded iPSC-Derived Armored CAR γδ T Cells as a Novel Cell Therapy to Treat Hepatocellular Carcinoma
Date and Time: Friday 06 November, 14:00 CET
Presenter: Stephanie Sonntag, Senior Research Scientist, iPSC Cell Therapy
Summary: We developed an allogeneic, off-the-shelf iPSC-derived armored CAR γδ T cell therapy for hepatocellular carcinoma (HCC) that combines scalable manufacturing with precise genome engineering. The immune-shielded cells incorporate a proprietary HCC-targeting CAR, γδ TCR, tumor microenvironment resistance mechanisms, and a safety switch, enabling robust trimodal tumor killing while avoiding allorejection. In vitro, the cells demonstrated a naïve, non-exhausted phenotype, strong anti-tumor activity, and resistance to NK- and T-cell-mediated elimination, supporting their potential as a broadly accessible cell therapy for solid tumors.